Zynerba Pharmaceuticals Inc. (ZYNE)

8.35
0.39 4.90
NASDAQ : Health Technology
Prev Close 7.96
Open 7.99
Day Low/High 7.97 / 8.48
52 Wk Low/High 2.75 / 16.47
Volume 624.16K
Avg Volume 983.80K
Exchange NASDAQ
Shares Outstanding 23.20M
Market Cap 183.73M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Zynerba Pharmaceuticals Is Now Oversold (ZYNE)

Zynerba Pharmaceuticals Is Now Oversold (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Wednesday Option Activity: ZYNE, TIF, DAKT

Notable Wednesday Option Activity: ZYNE, TIF, DAKT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zynerba Pharmaceuticals Inc , where a total of 4,815 contracts have traded so far, representing approximately 481,500 underlying shares. That amounts to about 78.8% of ZYNE's average daily trading volume over the past month of 611,390 shares.

Zynerba Pharma Looks Like Bad Medicine for Investors

Zynerba Pharma Looks Like Bad Medicine for Investors

The charts make ZYNE look bearish and not particularly attractive, so avoid.

Interesting ZYNE Put And Call Options For September 20th

Interesting ZYNE Put And Call Options For September 20th

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Jim Cramer says that in the heart of earnings season, Wall Street analysts can make important calls that let bulls push stocks higher.

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Jim Cramer takes a look at Berkshire Hathaway, Seattle Genetics, Zynerba Pharmaceuticals, Range Resources, Guardant Health, Danaher and more.

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Don't You Dare Say 'Bubble': Cramer's 'Mad Money' Recap (Wednesday 7/10/19)

Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Planet Fitness, Allergan, Amarin: 'Mad Money' Lightning Round

Jim Cramer weighs in on Planet Fitness, Allergan, Amarin, MPLX, Zynerba Pharmaceuticals, Schnieder National, United Parcel Service and more.

Interesting ZYNE Put And Call Options For February 2020

Interesting ZYNE Put And Call Options For February 2020

Investors in Zynerba Pharmaceuticals Inc saw new options become available this week, for the February 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of July 19th Options Trading For Zynerba Pharmaceuticals (ZYNE)

First Week Of July 19th Options Trading For Zynerba Pharmaceuticals (ZYNE)

Investors in Zynerba Pharmaceuticals Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

Uncertainty over the trade war's effects on earnings make this market really hard on investors, says Jim Cramer.

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Jim Cramer takes a look at Lululemon Athletica, Wayfair, Amazon, Intrexon, Iridium Communications, PayPal, Zscaler, Zynerba Pharmaceuticalsm and more.

Interesting ZYNE Put And Call Options For June 21st

Interesting ZYNE Put And Call Options For June 21st

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

There Is Generally Good Action on My Screens Today

There Is Generally Good Action on My Screens Today

The price action is quite good.

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

Market players are more skeptical of the quick moves on U.S.-China trade news.

5 Stocks on My Radar During a Quiet Day

5 Stocks on My Radar During a Quiet Day

Sometimes dull action like this can be good for trading.

Is Apple Aggressively Buying Back Its Stock?

Is Apple Aggressively Buying Back Its Stock?

Without Apple doing so well Monday the indices would look much different.

The Action in Select Small Caps Is Encouraging

The Action in Select Small Caps Is Encouraging

It's tough to do much while we await major news events.

First Week Of December 21st Options Trading For Zynerba Pharmaceuticals (ZYNE)

First Week Of December 21st Options Trading For Zynerba Pharmaceuticals (ZYNE)

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Insiders Find Value In These 3 Small Caps

Insiders Find Value In These 3 Small Caps

This sort of insider activity often coincides with a turnaround in these types of beaten down equities.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

Interesting ZYNE Put And Call Options For November 16th

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 210 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders

TheStreet Quant Rating: D- (Sell)